Eosinophilic Inflammation

Our ambition to address unmet needs for people living with inflammatory diseases driven by eosinophilic inflammation

Home / Our therapy areas / Eosinophilic Inflammation

Our commitment to uncovering eosinophilic inflammation and its impact across a range of diseases

We’re building on a 50-year heritage in respiratory care and following the science of common pathways and underlying disease drivers from respiratory disease into immunology-driven disease areas to better understand the important role of eosinophils as key effector cells in a range of potentially debilitating inflammatory diseases.

Some eosinophil-driven diseases have limited or no approved treatment options, creating a significant unmet need for innovative medicines. We know now that a process called eosinophilic inflammation may be responsible for the eosinophil recruitment and activation that is driving these diseases. Backed by a growing body of evidence, we’re committed to advancing the understanding of the role of eosinophils in inflammatory diseases across Respiratory & Immunology, with the aim to improve diagnosis, patient referrals and timely, appropriate treatment.
 

Learn about Eosinophilic Inflammation

What is eosinophilic inflammation?

When eosinophils are present in inflammatory disease, eosinophilic inflammation may be the cause. Knowledge of eosinophilic inflammation will help raise awareness that seemingly disparate diseases actually have a common cause – eosinophilic inflammation – that ties them all together.

Patient Charter

Representatives from eosinophilic patient organisations and clinicians formed a Patient Charter to encourage care reform for patients living with eosinophil associated diseases (EADs). It outlines four principles of quality care and clear steps to reduce the burden on patients:

  1. Greater awareness of EADs for patients, caregivers, health care professionals, and the general public
  2. Timely and accurate diagnosis
  3. Access to an appropriate multidisciplinary team
  4. Access to safe and effective treatment options

By addressing the need for more education among patients, healthcare professionals, and the public, the Charter continues to champion improved treatment options for the millions of people impacted by eosinophilic diseases worldwide1.

Learn more about the Patient Charter

Some of the eosinophil-driven diseases

We are currently exploring potential medicines across a broad range of diseases that may be driven by eosinophilic inflammation and where unmet medical need remains significant and, in some cases, where we see an increasing prevalence.

Abdulhammed_Babatunde

Bullous Pemphigoid (BP)
Abdulhammed_Babatunde

Eosinophilic Asthma (EA)
Abdulhammed_Babatunde

Chronic rhinosinusitis with nasal polyps (CRSwNP)
Abdulhammed_Babatunde

Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Abdulhammed_Babatunde

Hypereosinophilic Syndrome (HES)

References

1. Jackson, D. J., Akuthota, P., Andradas, R., et al. Improving care in eosinophil-associated diseases: A Charter. Advances in Therapy. 2022; 39 (6): 2323–2341.

2. Ramirez GA, Yacoub MR, Ripa M, et al. Eosinophils from physiology to disease: a comprehensive review. Biomed Res Int. 2018; 9095275.

3. National Organisation for Rare Disorders. Bullous Pemphigoid. Available at: http://rarediseases.org/rare-diseases/bullous-pemphigoid. [Last accessed: July 2023].

4. Wenzel SE. Severe asthma in adults. Am J Respir Crit Care Med. 2005; 172: 149-160.

5. Coumou H, Bel EH. Improving the diagnosis of eosinophilic asthma. Expert Rev Respir Med. 2016;10(10): 1093-1103.

6. Trivedi SG, Lloyd CM. Eosinophils in the pathogenesis of allergic airways disease. Cell Mol Life Sci. 2007; 64 (10): 1269-1289. 

7. American Partnership for Eosinophilic Disorders. Eosinophilic Granulomatosis with Polyangiitis (EGPA). Available at: http: apfed.org/about-ead/eosinophilic-granulomatosis-with-polyangiitis/. [Last accessed: July 2023].

8. Baldini C, Talarico R, Della Rossa A, Bombardieri S. Clinical Manifestations and Treatment of Churg-Strauss Syndrome. Rheum Dis Clin N Am. 2010; 36: 527-543. 

9. American Partnership for Eosinophilic Disorders. Hypereosinophilic Syndromes. Available at: http://apfed.org/about-ead/hypereosinophilic-syndrome/. [Last accessed: July 2023].

10. American Partnership for Eosinophilic Disorders. APFED Hypereosinophilic Syndromes Brochure. December 2017. Available at: http://apfed.org/wp-content/uploads/2017/12/APFED_HES_bro_final.pdf. [Last accessed: July 2023].

11. Bachert C, Akdis CA. Phenotypes and Emerging Endotypes of Chronic Rhinosinusitis. J Allergy Clin Immunol Pract. 2016; 4 (4): 621-628.

12. Newton JR, Ah-See KW. A review of nasal polyposis. Ther Clin Risk Manag. 2008; 4 (2): 507-512.

13. Fujieda S Imoto Y, Kato Y, et al. Eosinophilic chronic rhinosinusitis. Allergology Int. 2019; 68 (4): 403-412.

14. Hopkins C. Chronic Rhinosinusitis with Nasal Polyps. N Engl J Med. 2019; 381 (1): 55-63.

15. Stevens WW, Schleimer RP, Kern RC. Chronic Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract. 2016; 4 (4): 565-572.

16. Abdalla S, Alreefy H, Hopkins C. Prevalence of sinonasal outcome test (SNOT-22) symptoms in patients undergoing surgery for chronic rhinosinusitis in the England and Wales National prospective audit. Clin Otolaryngol. 2012; 37 (4): 276-282.

Veeva ID: Z4-55874
Date of preparation: August 2023